GILD

Business Context and Reporting Period

Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: Gilead is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for life-threatening infectious diseases, primarily HIV, Hepatitis B, and Hepatitis C. Key products include Truvada, Viread, Emtriva, Hepsera, AmBisome, and the newly launched Atripla (in collaboration with Bristol-Myers Squibb).

Key Financial Metrics

Note: Cash and marketable securities are derived from the balance sheet (Cash $559,580 + Short-term securities $2,294,368). Long-term securities of $350,495 are excluded from the liquidity summary above but included in total assets.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 52% year-over-year for the quarter (from $493.5M to $748.7M) and 50% for the nine-month period (from $1.42B to $2.13B). This was driven by a 53% increase in HIV product sales and a significant rise in royalty revenue from Tamiflu.
• Net Loss in Q3: The company reported a net loss of $52.2M for the quarter, compared to net income of $179.2M in the same period in 2005. This was primarily due to a non-cash, non-deductible charge of $355.6M for purchased in-process research and development (IPR&D) related to the Corus Pharma acquisition.
• Product Mix: Truvada sales grew 90% year-over-year to $309.0M. Atripla, launched in July 2006, generated $68.4M in sales. Conversely, Viread sales declined 10% as patients switched to combination therapies.
• Accounting Changes: Adoption of SFAS 123R (Share-Based Payment) on January 1, 2006, resulted in significant stock-based compensation expenses ($25.6M for the quarter, $76.8M for nine months), impacting operating margins.

Guidance, Outlook, and Risks

• Acquisitions: Gilead completed the acquisition of Corus Pharma ($414.7M purchase price) and Raylo Chemicals ($136M). In October 2006, the company signed a definitive agreement to acquire Myogen, Inc. for approximately $2.5 billion, expected to close in Q4 2006.
• Full Year 2006 Guidance:
  • HIV Product Sales: Expected to be in the range of $2.00 billion to $2.05 billion.
  • AmBisome Sales: Expected to be in the range of $205.0 million to $215.0 million.
  • Hepsera Sales: Expected to be in the range of $215.0 million to $225.0 million.
  • R&D Expenses: Expected to be in the range of $365.0 million to $385.0 million.
  • SG&A Expenses: Expected to be in the range of $555.0 million to $575.0 million.
  • Gross Margin: Expected to be in the range of 84% to 85%.
• Risks and Contingencies:
  • Legal Proceedings: Pending litigation regarding Medicaid reimbursement pricing in New York, Alabama, and Mississippi. A securities class action lawsuit was dismissed but appealed.
  • Regulatory: Risks associated with the approval of the Corus product candidate (aztreonam lysine) and potential compulsory licensing of Tamiflu or HIV products in developing nations.
  • Integration: Risks related to integrating Corus, Raylo, and the pending Myogen acquisition.

Investor Verification Checklist

• Corus Acquisition Impact: Verify the commercial viability and regulatory timeline for the aztreonam lysine program, which accounted for a $355.6M non-deductible charge.
• Myogen Acquisition: Confirm the closing conditions and financing details for the $2.5 billion Myogen acquisition, including the potential for a material IPR&D charge upon closing.
• Tamiflu Royalty Volatility: Assess the sustainability of Tamiflu royalty revenue, which is highly dependent on Roche's pandemic planning sales and government contracts.
• Stock-Based Compensation: Review the long-term impact of SFAS 123R adoption on future earnings, noting $236.4M of unrecognized expense remaining.
• European Receivables: Monitor the $300.5M in accounts receivable from European government customers, which are subject to payment delays and credit risk.